Close Menu

Waters

Agilent this week introduced its AdvanceBio Peptide Mapping BioHPLC and ZORBAX RRHD 300-HILIC columns for the analysis of proteins, monoclonal antibodies, peptides and additional biologics.

Bruker's shareholders have re-elected its class 1 directors to serve until the company's 2016 shareholder meeting, including Wolf-Dieter Emmerich; Brenda Furlong; Frank Laukien; and Richard Packer.

NEW YORK (GenomeWeb News) – Waters today reported that its revenues in the first quarter were up 2 percent year over year, driven by a resurgence in instrument sales, particularly mass spectrometers.

Waters announced this week that it has named the St. John's Research Institute in Bangalore, India, a Center of Excellence.

Thermo Fisher Scientific said this week that two of its facilities have achieved ISO 13485 certification, moving the company forward in its efforts to develop liquid chromatography-mass spectrometry systems for clinical use.

VICAM, a business of Waters, this week introduced its new Myco6in1+ LC/MS/MS immunoaffinity column for detection of mycotoxins.

Bruker last week introduced its benchtop Compact LC-QqTOF mass spectrometer.

Proteomics research continues to be a booming business in China, with the market over the last few years having grown at around 30 percent to 35 percent annually, according to estimates from biotech consulting firm JZMed.

NEW YORK (GenomeWeb News) – A German court has ruled in favor of Agilent Technologies in a patent infringement case against Waters dating back to 2005, Waters disclosed in its Form 10-K.

Waters this week introduced a number of new products for protein and glycan analysis, including its new Acquity UPLC CSH130 C18 columns, its XSelect HPLC CSH130 C18 columns, and three GlycoWorks kits for glycan labeling and sampl

Pages

The US Patent and Trademark Office is opening another interference proceeding in the CRISPR patent fight.

There's increasing genetic evidence that a number of ancient hominins may have contributed to the human gene pool, according to Discover's The Crux blog.

The Japan News writes that Japan needs to seize the opportunity to ensure that a wide number of people benefit from personalized cancer treatments.

In Cell this week: messenger RNA expression and translation, RNA localization atlas, and more.